The Wall Street Journal reports, contrary to his testimony, HHS nominee Rep. Tom Price was offered a privileged price for a biotech stock that he purchased. Senate Democrats will seek to delay a scheduled Tuesday vote on him. Democrats are wondering why HHS stopped advertising open enrollment. A group of them sent a letter to the acting HHS Secretary. 